Zanolimumab

Drug Profile

Zanolimumab

Alternative Names: Anti-CD4 monoclonal antibody HuMax-CD4™; Anti-CD4 monoclonal antibody MDX CD4; HuMax-CD4; MDX CD4; MDX-016

Latest Information Update: 09 Sep 2015

Price : $50

At a glance

  • Originator Genmab
  • Developer Emergent BioSolutions; Genmab
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cutaneous T cell lymphoma; Peripheral T-cell lymphoma; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 06 Jun 2011 Zanolimumab licensed to Emergent BioSolutions worldwide
  • 31 Dec 2010 Suspended - Phase-III for Cutaneous T-cell lymphoma in European Union (IV)
  • 31 Dec 2010 Suspended - Phase-III for Cutaneous T-cell lymphoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top